NRx Pharmaceuticals announced on June 2, 2026, its intention to conduct an underwritten public offering of its common stock. The size and terms of the offering are subject to market conditions and have not yet been determined.
Key Details
- Offering Type: Underwritten public offering of common stock, par value $0.001 per share.
- Use of Proceeds: Intended for working capital and general corporate purposes to support growth.
- Underwriter Option: The underwriter has a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering.
- Lead Bookrunner: BTIG, LLC is acting as the lead bookrunner for the proposed offering.